Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry.

[1]  Jerome P. Reiter,et al.  A comparison of two methods of estimating propensity scores after multiple imputation , 2016, Statistical methods in medical research.

[2]  T. Choueiri,et al.  Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. , 2014, European urology.

[3]  M. Dimopoulos,et al.  Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study. , 2014, Clinical genitourinary cancer.

[4]  M. Gore,et al.  Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma , 2013, British Journal of Cancer.

[5]  Sunita Ghosh,et al.  A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[6]  J. Ferlay,et al.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.

[7]  L. Goossens.  Underestimated uncertainties. Hospital-at-home for COPD exacerbations and methodological issues in the economic evaluation of healthcare , 2013 .

[8]  Pierre I Karakiewicz,et al.  Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. , 2011, European urology.

[9]  C. Blank,et al.  A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ. , 2011, Urology.

[10]  D. Berney,et al.  The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. , 2011, European urology.

[11]  P. Austin.  An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies , 2011, Multivariate behavioral research.

[12]  Patrick Royston,et al.  Multiple imputation using chained equations: Issues and guidance for practice , 2011, Statistics in medicine.

[13]  Lorenzo Marconi,et al.  EAU guidelines on renal cell carcinoma: 2014 update. , 2010, European urology.

[14]  B. Teh,et al.  Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. , 2010, The Journal of urology.

[15]  C. Porta,et al.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  E. Wallen,et al.  Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Elizabeth A Stuart,et al.  Matching methods for causal inference: A review and a look forward. , 2010, Statistical science : a review journal of the Institute of Mathematical Statistics.

[18]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Millikan,et al.  Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Xin Huang,et al.  Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C. Charbonneau,et al.  Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. , 2008, Cancer treatment reviews.

[22]  C. Tangen,et al.  Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. , 2005, The Journal of urology.

[23]  Sascha O. Becker,et al.  Estimation of Average Treatment Effects Based on Propensity Scores , 2002 .

[24]  N. Munshi,et al.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. , 2001, The New England journal of medicine.

[25]  R. Sylvester,et al.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial , 2001, The Lancet.

[26]  Gareth Griffiths,et al.  Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. , 1999, Lancet.

[27]  P. Fayers,et al.  Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial , 1999 .

[28]  T. Choueiri,et al.  The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. , 2011, The Journal of urology.

[29]  R. Motzer,et al.  Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.